Tuberculosis Drugs Market To Exhibit A Rise By 5.3% CAGR Between 2019 To 2027 | Coherent Market Insights

Tuberculosis Drugs Market – Insights

Tuberculosis (TB) is a chronic condition that usually affects the lungs. The treatment of TB is divided into three types: first line treatment, second line treatment, and drug resistant treatment. Majority of TB cases require up to six months of treatment using existing therapies. Use of advanced technologies and development of novel therapies is expected to improve treatment of TB and reduce the duration required. Moreover, enhancing patient access to appropriate TB medicines particularly in the areas of multidrug-resistant TB (MDR TB) and pediatric TB is also expected to aid in reducing the prevalence of the disease.

The global tuberculosis drugs market was valued at US$ 1,146.5 million in 2019, and is expected to exhibit a CAGR of 5.3% over the forecast period (2019 – 2027).

Get PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/191

The increasing funding and expenditure on TB treatment and research are expected to drive growth of the market over the forecast period. For instance, according to the WHO, the global TB-related funding to 119 emerging economies accounted for around US$ 6.9 billion in 2018, from US$ 3.3 billion in 2006, where 86% of the total funding was provided by Brazil, Russia, India, China, and South Africa (BRICS). Furthermore, increasing number of product approvals and research and drug development activities are expected to fuel growth of the market. For instance, in 2019, TB Alliance received the U.S. FDA approval for its drug, Pretomanid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. Additionally, the tuberculosis drugs market is expected to witness significant growth over the forecast period, owing to increasing incidence of TB globally. For instance, according to the WHO Global Tuberculosis Report 2018, around 10 million people suffered from TB disease in 2017, which included 5.8 million men, 3.2 million women, and 1.0 million children.

Moreover, key players operating in this market are focusing on adopting collaboration strategies to cater to the increasing demand of TB treatment drugs. For instance, in 2015, Dishman Pharmaceuticals and Chemicals Limited entered into a license collaboration with Johnson & Johnson to manufacture raw material for drugs used in the treatment of multi drug resistant tuberculosis (MDR-TB).

Global Tuberculosis Drugs Market Share (%) Analysis, by Therapy Type, 2019

Source: Coherent Market Insights Analysis (2019)

Quick Buy – Tuberculosis Drugs Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/191

Tuberculosis Drugs Market: Drivers

Increasing focus R&D of drugs that can shorten the duration of treatment and help overcome the challenges of drug-susceptible TB and drug-resistant TB is expected to boost growth the global tuberculosis drugs market. For instance, in August 2019, TB Alliance received the U.S. FDA approval for Pretomnid, a combination regimen with bedaquiline and linezolid, which is developed and indicated for the treatment of patients with XDR-TB, or intolerant non-responsive MDR-TB.

Moreover, increasing cases of TB worldwide is also propelling growth of the market. For instance, according to World Health Organization’s (WHO’s) Global Tuberculosis Report 2018, around 10 million people worldwide suffered from TB in 2017.

Tuberculosis Drugs Market: Restraints

A major factor hampering growth of the market is increasing cases of drug recall. For instance, in 2018, Sandoz recalled its batch of wrongly-packed TB drugs in India. In 2016, Philippines Food and Drug Administration recalled Novartis’ Onecure for insufficient amount of rifampicin in the drug. High prices of drugs is also expected to hinder growth of the market. Second line treatment drugs are highly priced compared to first line treatment.

Tuberculosis Drugs Market: Regional Insights

North America is expected to account for the largest market share in the global tuberculosis drugs market over the forecast period. This is attributed to high cost of TB drugs in the region. For instance, in 2015, the price of Cycloserine drug used for the treatment of MDR TB was increased from US$ 15 per tablet to US$ 360 per tablet, owing to transfer of rights to Rodelis Therapeutics.

Increasing incidence of TB is expected to boost growth of the market in Europe. For instance, according to the TB Europe Coalition, in 2015, about 323,000 new TB cases and 32,000 deaths were reported in Europe.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/asia-pacific-to-be-growth-engine-as-tuberculosis-drugs-market-surges-past-us-2-billion-by-2024-184

Global Tuberculosis Drugs Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Source: Coherent Market Insights Analysis (2019)

 Tuberculosis Drugs Market: Competitive Landscape

Key players in the market are focused on adopting collaboration strategies to expand their product portfolio. For instance, in April 2019, Mylan, a pharmaceuticals company, collaborated with TB Alliance to commercialize the Pretomanid drug for the treatment of pulmonary TB.

Major players operating in the global tuberculosis drugs market include, Novartis AG, Macleods Pharmaceuticals Ltd., Johnson & Johnson Services, LLC, Lupin Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., and others.

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837